Cargando…

A new algorithm to convert a normal antibody into the corresponding catalytic antibody

Over thousands of monoclonal antibodies (mAbs) have been produced so far, and it would be valuable if these mAbs could be directly converted into catalytic antibodies. We have designed a system to realize the above concept by deleting Pro(95), a highly conserved residue in CDR-3 of the antibody ligh...

Descripción completa

Detalles Bibliográficos
Autores principales: Hifumi, Emi, Taguchi, Hiroaki, Tsuda, Haruna, Minagawa, Tetsuro, Nonaka, Tamami, Uda, Taizo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096177/
https://www.ncbi.nlm.nih.gov/pubmed/32232151
http://dx.doi.org/10.1126/sciadv.aay6441
_version_ 1783510764212977664
author Hifumi, Emi
Taguchi, Hiroaki
Tsuda, Haruna
Minagawa, Tetsuro
Nonaka, Tamami
Uda, Taizo
author_facet Hifumi, Emi
Taguchi, Hiroaki
Tsuda, Haruna
Minagawa, Tetsuro
Nonaka, Tamami
Uda, Taizo
author_sort Hifumi, Emi
collection PubMed
description Over thousands of monoclonal antibodies (mAbs) have been produced so far, and it would be valuable if these mAbs could be directly converted into catalytic antibodies. We have designed a system to realize the above concept by deleting Pro(95), a highly conserved residue in CDR-3 of the antibody light chain. The deletion of Pro(95) is a key contributor to catalytic function of the light chain. The S35 and S38 light chains have identical amino acid sequences except for Pro(95). The former, with Pro(95) did not show any catalytic activity, whereas the latter, without Pro(95), exhibited peptidase activity. To verify the generality of this finding, we tested another light chain, T99wt, which had Pro(95) and showed little catalytic activity. In contrast, a Pro(95)-deleted mutant enzymatically degraded the peptide substrate and amyloid-beta molecule. These two cases demonstrate the potential for a new method of creating catalytic antibodies from the corresponding mAbs.
format Online
Article
Text
id pubmed-7096177
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-70961772020-03-30 A new algorithm to convert a normal antibody into the corresponding catalytic antibody Hifumi, Emi Taguchi, Hiroaki Tsuda, Haruna Minagawa, Tetsuro Nonaka, Tamami Uda, Taizo Sci Adv Research Articles Over thousands of monoclonal antibodies (mAbs) have been produced so far, and it would be valuable if these mAbs could be directly converted into catalytic antibodies. We have designed a system to realize the above concept by deleting Pro(95), a highly conserved residue in CDR-3 of the antibody light chain. The deletion of Pro(95) is a key contributor to catalytic function of the light chain. The S35 and S38 light chains have identical amino acid sequences except for Pro(95). The former, with Pro(95) did not show any catalytic activity, whereas the latter, without Pro(95), exhibited peptidase activity. To verify the generality of this finding, we tested another light chain, T99wt, which had Pro(95) and showed little catalytic activity. In contrast, a Pro(95)-deleted mutant enzymatically degraded the peptide substrate and amyloid-beta molecule. These two cases demonstrate the potential for a new method of creating catalytic antibodies from the corresponding mAbs. American Association for the Advancement of Science 2020-03-25 /pmc/articles/PMC7096177/ /pubmed/32232151 http://dx.doi.org/10.1126/sciadv.aay6441 Text en Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (http://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.
spellingShingle Research Articles
Hifumi, Emi
Taguchi, Hiroaki
Tsuda, Haruna
Minagawa, Tetsuro
Nonaka, Tamami
Uda, Taizo
A new algorithm to convert a normal antibody into the corresponding catalytic antibody
title A new algorithm to convert a normal antibody into the corresponding catalytic antibody
title_full A new algorithm to convert a normal antibody into the corresponding catalytic antibody
title_fullStr A new algorithm to convert a normal antibody into the corresponding catalytic antibody
title_full_unstemmed A new algorithm to convert a normal antibody into the corresponding catalytic antibody
title_short A new algorithm to convert a normal antibody into the corresponding catalytic antibody
title_sort new algorithm to convert a normal antibody into the corresponding catalytic antibody
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096177/
https://www.ncbi.nlm.nih.gov/pubmed/32232151
http://dx.doi.org/10.1126/sciadv.aay6441
work_keys_str_mv AT hifumiemi anewalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody
AT taguchihiroaki anewalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody
AT tsudaharuna anewalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody
AT minagawatetsuro anewalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody
AT nonakatamami anewalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody
AT udataizo anewalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody
AT hifumiemi newalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody
AT taguchihiroaki newalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody
AT tsudaharuna newalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody
AT minagawatetsuro newalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody
AT nonakatamami newalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody
AT udataizo newalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody